Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Sangamo Therapeutics Receives Rare Pediatric Disease Designation From FDA For SB-318 In Vivo Genome Editing Therapeutic For MPS I

Piper Jaffray Remains Sidelined on Sangamo Biosciences (SGMO) Following 4Q Report

February 28, 2017 12:01 PM EST

Piper Jaffray reiterated a Neutral rating and $5.00 price target on Sangamo BioSciences (NASDAQ: SGMO) following the company's 4Q earnings report. Sangamo reported 4Q16 revenues of $8.9M, slightly above projections, and opex of $18.8M, slightly below projections.

Analyst Charles Duncan commented, "Today Sangamo reported 4Q16 financial... More